Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 24.52, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.51M shares, decreasing 16.27% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 1.58M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.66.